Is RNXT or RYTM more undervalued in 2026?

CirclFi compares RenovoRx, Inc. (RNXT) and Rhythm Pharmaceuticals, Inc. (RYTM) using 13 institutional-grade valuation models. RNXT has a Quality of Company score of 4.9/10 while RYTM scores 6.1/10.

Which is a better buy — RNXT or RYTM?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do RNXT and RYTM valuations compare?

RNXT at $0.91 and RYTM at $88.32 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

RNXT vs RYTM Valuation Comparison 2026 — Intrinsic Value Analysis

RNXT

Pharmaceutical Preparations

RenovoRx, Inc.

Quality

4.9

out of 10

Value Trap

SAFE

Price

$0.91

Last close

Models

11/13

Active

RYTM

Pharmaceutical Preparations

Rhythm Pharmaceuticals, Inc.

Quality

6.1

out of 10

Value Trap

SAFE

Price

$88.32

Last close

Models

12/13

Active

Model-by-Model Comparison

Model	Type	RNXT Fair Value	RNXT Upside	RYTM Fair Value	RYTM Upside
Bayesian DCF	Intrinsic	$0.37	-59.1%	$26.22	-70.3%
Earnings Power Value	Intrinsic	$1.13	+27.8%	$3.54	-95.7%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for RNXT vs RYTM — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

RNXT vs RYTM — Which Stock Is More Undervalued?

RYTM scores higher with a 6.1/10 quality rating vs RNXT's 4.9/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing RenovoRx, Inc. (RNXT) and Rhythm Pharmaceuticals, Inc. (RYTM) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

RNXT currently trades at $0.91 with a QOC of 4.9/10, while RYTM trades at $88.32 with a QOC of 6.1/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).